Enumeral was a Cambridge, Massachusetts-based biotechnology company which developed monoclonal antibody immunotherapies through an 'immunoprofiling' platform that allowed it to scan the human immune microenvironment and identify and validate potential drug candidates.
[4] The company's Scientific Founder was Christopher Love, Associate Professor of Chemical Engineering at MIT;[5] the Executive Chairman is John Rydzewskand and its CEO is Arthur Tinkelenberg.
[10] In January 2018, Enumeral struck a deal with Xoma Corporation, located in the San Francisco Bay Area, to sell its assets for US$1.6 million, while concurrently filing for Chapter 11 bankruptcy.
[1][2]: item 1.03 Enumeral's platform consists of various proprietary cellular libraries derived from target-specific immunized sources or from human patient donors.
The platform has three main parts: An early commercial interest of Enumeral has focused on PD-1, currently targeted by two FDA-approved monoclonal antibody drugs - Keytruda, from Merck & Co., and Opdivo, from Bristol-Myers Squibb.